News

Call for Judges for Science Fair and BioGENEius Challenge

Each year, Virginia Bio recruits volunteer judges from the membership to attend the Virginia State Science and Engineering Fair to select the top three winners in the field of biosciences. This year’s fair will be held virtually on April 10, 2021, hosted virtually by the Virginia Tech Carilion School of Medicine in Roanoke’s Berglund Special Events Center. Judges will be sent applicant information, abstracts and posters to review.

Volunteer judges are also needed for the Virginia BioGENEius Challenge. Students submit their projects in either the categories of biotechnology, agriculture or industrial/ environmental science. The judging for the challenge is done virtually. Judges will be sent applicant information, abstracts and posters by May 10, and results will be due back to Virginia Bio on May 19. Winners from the state challenge will go on to compete in the U.S. National BioGENEius Challenge taking place during the BIO International Conference in June.

Please contact Caron Trumbo if interested in volunteering your time!

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules